vs
Side-by-side financial comparison of ACNB CORP (ACNB) and Adaptive Biotechnologies Corp (ADPT). Click either name above to swap in a different company.
Adaptive Biotechnologies Corp is the larger business by last-quarter revenue ($71.7M vs $47.2M, roughly 1.5× ACNB CORP). ACNB CORP runs the higher net margin — 22.9% vs -18.9%, a 41.8% gap on every dollar of revenue. On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (51.0% vs 42.2%). ACNB CORP produced more free cash flow last quarter ($52.6M vs $1.4M). Over the past eight quarters, Adaptive Biotechnologies Corp's revenue compounded faster (30.8% CAGR vs 22.1%).
ACNB Corp is a US-based financial holding company headquartered in Pennsylvania. It provides a full suite of financial solutions including retail and commercial banking, wealth management, trust services, and property & casualty insurance products. Its core market covers local communities, individual consumers, and small-to-medium enterprises across south-central Pennsylvania and northern Maryland.
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
ACNB vs ADPT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.2M | $71.7M |
| Net Profit | $10.8M | $-13.6M |
| Gross Margin | — | 74.6% |
| Operating Margin | 27.9% | -17.8% |
| Net Margin | 22.9% | -18.9% |
| Revenue YoY | 42.2% | 51.0% |
| Net Profit YoY | 63.8% | 59.7% |
| EPS (diluted) | $1.10 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.2M | $71.7M | ||
| Q3 25 | $50.9M | $94.0M | ||
| Q2 25 | $50.3M | $58.9M | ||
| Q1 25 | $43.5M | $52.4M | ||
| Q4 24 | $33.2M | $47.5M | ||
| Q3 24 | $34.1M | $46.4M | ||
| Q2 24 | $33.3M | $43.2M | ||
| Q1 24 | $31.6M | $41.9M |
| Q4 25 | $10.8M | $-13.6M | ||
| Q3 25 | $14.9M | $9.5M | ||
| Q2 25 | $11.6M | $-25.6M | ||
| Q1 25 | $-272.0K | $-29.9M | ||
| Q4 24 | $6.6M | $-33.7M | ||
| Q3 24 | $7.2M | $-32.1M | ||
| Q2 24 | $11.3M | $-46.2M | ||
| Q1 24 | $6.8M | $-47.5M |
| Q4 25 | — | 74.6% | ||
| Q3 25 | — | 80.7% | ||
| Q2 25 | — | 69.4% | ||
| Q1 25 | — | 67.6% | ||
| Q4 24 | — | 62.0% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 55.3% | ||
| Q1 24 | — | 56.9% |
| Q4 25 | 27.9% | -17.8% | ||
| Q3 25 | 37.2% | 10.9% | ||
| Q2 25 | 29.7% | -42.5% | ||
| Q1 25 | -1.3% | -56.4% | ||
| Q4 24 | 24.8% | -71.3% | ||
| Q3 24 | 27.6% | -70.3% | ||
| Q2 24 | 42.8% | -109.6% | ||
| Q1 24 | 26.9% | -116.5% |
| Q4 25 | 22.9% | -18.9% | ||
| Q3 25 | 29.2% | 10.2% | ||
| Q2 25 | 23.2% | -43.5% | ||
| Q1 25 | -0.6% | -56.9% | ||
| Q4 24 | 19.9% | -71.0% | ||
| Q3 24 | 21.1% | -69.1% | ||
| Q2 24 | 33.9% | -107.0% | ||
| Q1 24 | 21.4% | -113.5% |
| Q4 25 | $1.10 | $-0.08 | ||
| Q3 25 | $1.42 | $0.06 | ||
| Q2 25 | $1.11 | $-0.17 | ||
| Q1 25 | $-0.03 | $-0.20 | ||
| Q4 24 | $0.77 | $-0.22 | ||
| Q3 24 | $0.84 | $-0.22 | ||
| Q2 24 | $1.32 | $-0.31 | ||
| Q1 24 | $0.80 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $65.6M | $70.5M |
| Total DebtLower is stronger | $255.4M | — |
| Stockholders' EquityBook value | $420.0M | $218.8M |
| Total Assets | $3.2B | $512.7M |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $65.6M | $70.5M | ||
| Q3 25 | $102.1M | $55.0M | ||
| Q2 25 | $103.1M | $43.2M | ||
| Q1 25 | $123.6M | $50.6M | ||
| Q4 24 | $47.3M | $47.9M | ||
| Q3 24 | $58.1M | $38.1M | ||
| Q2 24 | $86.3M | $59.8M | ||
| Q1 24 | $53.1M | $71.2M |
| Q4 25 | $255.4M | — | ||
| Q3 25 | $255.4M | — | ||
| Q2 25 | $255.4M | — | ||
| Q1 25 | $255.3M | — | ||
| Q4 24 | $255.3M | — | ||
| Q3 24 | $255.3M | — | ||
| Q2 24 | $255.3M | — | ||
| Q1 24 | $255.3M | — |
| Q4 25 | $420.0M | $218.8M | ||
| Q3 25 | $408.6M | $204.4M | ||
| Q2 25 | $395.2M | $179.7M | ||
| Q1 25 | $386.9M | $190.4M | ||
| Q4 24 | $303.3M | $202.7M | ||
| Q3 24 | $306.8M | $223.8M | ||
| Q2 24 | $289.3M | $241.6M | ||
| Q1 24 | $279.9M | $274.9M |
| Q4 25 | $3.2B | $512.7M | ||
| Q3 25 | $3.3B | $490.6M | ||
| Q2 25 | $3.3B | $496.6M | ||
| Q1 25 | $3.3B | $510.9M | ||
| Q4 24 | $2.4B | $539.4M | ||
| Q3 24 | $2.4B | $558.5M | ||
| Q2 24 | $2.5B | $584.9M | ||
| Q1 24 | $2.4B | $620.3M |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.62× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.84× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.88× | — | ||
| Q1 24 | 0.91× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $53.6M | $2.1M |
| Free Cash FlowOCF − Capex | $52.6M | $1.4M |
| FCF MarginFCF / Revenue | 111.4% | 2.0% |
| Capex IntensityCapex / Revenue | 2.3% | 0.9% |
| Cash ConversionOCF / Net Profit | 4.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | $92.2M | $-48.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.6M | $2.1M | ||
| Q3 25 | $23.2M | $-7.1M | ||
| Q2 25 | $17.8M | $-12.4M | ||
| Q1 25 | $-71.0K | $-28.5M | ||
| Q4 24 | $39.8M | $-12.5M | ||
| Q3 24 | $13.6M | $-27.1M | ||
| Q2 24 | $9.7M | $-17.3M | ||
| Q1 24 | $10.8M | $-38.4M |
| Q4 25 | $52.6M | $1.4M | ||
| Q3 25 | $22.8M | $-7.5M | ||
| Q2 25 | $17.6M | $-13.1M | ||
| Q1 25 | $-730.0K | $-29.7M | ||
| Q4 24 | $38.8M | $-12.6M | ||
| Q3 24 | $13.3M | $-27.4M | ||
| Q2 24 | $9.4M | $-19.0M | ||
| Q1 24 | $10.7M | $-39.9M |
| Q4 25 | 111.4% | 2.0% | ||
| Q3 25 | 44.7% | -8.0% | ||
| Q2 25 | 35.0% | -22.2% | ||
| Q1 25 | -1.7% | -56.7% | ||
| Q4 24 | 117.0% | -26.5% | ||
| Q3 24 | 39.1% | -59.0% | ||
| Q2 24 | 28.3% | -44.1% | ||
| Q1 24 | 33.9% | -95.2% |
| Q4 25 | 2.3% | 0.9% | ||
| Q3 25 | 0.8% | 0.4% | ||
| Q2 25 | 0.4% | 1.1% | ||
| Q1 25 | 1.5% | 2.4% | ||
| Q4 24 | 2.9% | 0.2% | ||
| Q3 24 | 0.7% | 0.7% | ||
| Q2 24 | 0.9% | 4.0% | ||
| Q1 24 | 0.2% | 3.6% |
| Q4 25 | 4.96× | — | ||
| Q3 25 | 1.56× | -0.75× | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.03× | — | ||
| Q3 24 | 1.88× | — | ||
| Q2 24 | 0.86× | — | ||
| Q1 24 | 1.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACNB
Segment breakdown not available.
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
